Navigation Links
Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
Date:12/20/2013

the Board, commented: "I am delighted to welcome Annika to Symphogen. Annika's extensive experience in both the healthcare industry and financial markets makes her a perfect addition to the Board.  Annika's skills, knowledge and experience will be invaluable to furthering the success of Symphogen."

Annika Espander Jansson added: "I am very excited to take part in the development of Symphogen which operates in a very important medical area with significant unmet medical needs and with a business concept aiming at improving therapies for cancer patients."

About Symphogen A/S  

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market.

The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its oncology pipeline and has currently brought two product candidates into the clinic. The company's productive technology suite - capable of identifying, selecting and manufacturing optimal antibody mixtures - fuels Symphogen's innovative pipeline.

The lead oncology product, Sym004, was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.

In total, the company has raised €249 million in equity capital from premier international investors including Novo, Essex Woodlands Health Ventures and PKA, and employs 95 people, most of whom are based at Symphogen's facilities in Copenhagen.

For additional information, please contact:
Kirsten Drejer
Chief Executive Officer
Phone: +45-22-10-99-59
E-mail: kd@symphogen.com

Martin Olin
Chief Financial Officer
Phone:
'/>"/>

SOURCE Symphogen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
3. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
4. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
5. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
6. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
7. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
8. Pittcon Announces the 2014 Technical Program
9. AudioNotch Tinnitus Treatment Announces Holiday Sale
10. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
11. DryLet, LLC Announces Investment from Ronald A. Chisholm Limited to Support Growth and Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Editor Note: For more information about this ... ago, Analysts Review released new research updates concerning several important ... SSH ), Synergetics USA (NASDAQ: ... Spectranetics (NASDAQ: SPNC ), and Thoratec (NASDAQ: ... for investors, to hear about what matters - proudly employing ...
(Date:3/2/2015)... Massachusetts (PRWEB) March 02, 2015 Outside ... services, today announced the addition of Debbie Casey as ... capabilities in the healthcare space. , Debbie ... most of which with Fresenius Medical Care North America ... leverage her extensive experience to work with Outside GC’s ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Outside GC Expands Healthcare Team 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... YORK, March 7, 2011 Reportlinker.com announces ... available in its catalogue: ... Japan - Emerging Opportunities and Business Expansion ... http://www.reportlinker.com/p0365328/The-2011-Blood-Banking-Market-US-Europe-Japan---Emerging-Opportunities-and-Business-Expansion-Strategies-for-Suppliers.html During the next ...
... 2011 Champions Biotechnology, Inc. (OTC: CSBR), today announced its ... 2011. Fiscal 2011 Third Quarter Financial Highlights ... an increase of 278% compared to the third quarter of ... excluding stock based compensation of $796,000* Net ...
... the world of nanoparticles has now become a possibility, thanks ... UCSB research team has developed a new instrument capable of ... tens of nanometers. The study will be published on line ... the April print issue of the journal. "This ...
Cached Biology Technology:Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers 2Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 6New instrument keeps an 'eye' on nanoparticles 2
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... microbes living in their roots, according to new research at ... carbon cycle that is vital to life on earth. ... to make sugar by combining water with carbon dioxide from ... scientists in the Universitys Department of Biology discovered that some ...
... a mucky Florida swamp have given scientists a window ... 15 million to 130 million years old. Scientists ... Natural History in Berlin made the landmark discovery that ... unwittingly swim into resin flowing down into the water ...
... Bats are the most vocal mammals other than ... outings could lead to better treatments for human speech ... of bats native to Central Texas fly overhead each ... frequencies too high for humans to hear. Texas ...
Cached Biology News:Hungry microbes share out the carbon in the roots of plants 2Scientists find how amber becomes death trap for watery creatures 2Scientists find how amber becomes death trap for watery creatures 3Researchers studying how singing bats communicate 2
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Biology Products: